Vmbook Online ordering

Synageva Biopharma Corp

George Clinical (GEVA) is a global contract research organization (CRO) that specializes in clinical trial services for the biotechnology and pharmaceutical industries. The company is headquartered in Sydney, Australia and is listed on the Australian Securities Exchange (ASX: GEVA).

In terms of financials, George Clinical reported revenue of AUD 82.5 million (~USD 61.6 million) for the fiscal year ended June 30, 2022, representing an increase of 25.4% compared to the previous fiscal year. The company's net profit after tax for the fiscal year was AUD 6.1 million (~USD 4.6 million), up from a loss of AUD 1.5 million (~USD 1.1 million) in the previous fiscal year.

Regarding growth, George Clinical has been expanding its operations in recent years through strategic partnerships and acquisitions. In 2021, the company acquired Clinical Development Services Africa (CDSA), a South African CRO, to strengthen its presence in the African market. George Clinical has also established a number of partnerships with institutions and organizations in the Asia-Pacific region, including the National University of Singapore and the Chinese University of Hong Kong.

In terms of valuation, George Clinical has a market capitalization of approximately AUD 156.5 million (~USD 116.8 million) as of March 15, 2023. The company's price-to-earnings (P/E) ratio is approximately 21.5, based on its trailing twelve-month earnings.

Regarding dividends, George Clinical has not paid a dividend since its initial public offering in 2014. Instead, the company has been reinvesting its profits into growth initiatives and expanding its operations.

It's important to note that investing in individual stocks, including George Clinical, carries risks, and potential investors should conduct their own due diligence before making any investment decisions. The information provided here is for informational purposes only and should not be construed as investment advice.